Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
The Pharma Letter6d
New Phase IIIb data show Novartis Fabhalta improved hemoglobin levels
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...
Novartis reports new Phase 3B data for Fabhalta
Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...
Pharmabiz5d
New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy
New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...
Novartis reports positive Phase 3b data for Fabhalta in PNH
Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...
The American Journal of Managed Care6d
New Data Reinforce Iptacopan's Role in Transforming PNH Care With Hemoglobin, QOL Gains
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...
ENDPOINTS NEWS6d
No­var­tis bol­sters Fab­hal­ta da­ta in com­pe­ti­tion with As­traZeneca
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...